European Research Initiative on CLL

ERIC | Completed Projects


Recurrent Mutations in CLL

    Coordinators: P. Baliakas, A. Hadzidimitriou, J. Strefford, K. Stamatopoulos, R. Rosenquist
    » more

TP53 Gene Abnormalities

  • P53 function project
    Coordinators: A. Kater, Amsterdam/The Netherlands; S. Stilgenbauer, Ulm/Germany
    Publications: Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia
    G. Doreen te Raa, J. Malcikova, S. Pospisilova, M. Trbusek, M. Mraz, M. Le Garff-Tavernier, H. Merle-Béral, K. Lin, A.Pettitt, O.Merkel, T.Stankovic, M. van Oers, E. Eldering, S. Stilgenbauer, T. Zenz, A. Kater, European Research initiative on CLL (ERIC) Leukemia & Lymphoma
    Publications: Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach G. Doreen te Raa, J. Malcikova, M. Mraz, M. Trbusek, M. Le Garff-Tavernier, H. Merle-Beral, R. Greil, O. Merkel, S. Pospisilova, K. Lin, AR. Pettitt, T. Stankovic, M. H. van Oers, E. Eldering, S. Stilgenbauer, T. Zenz, A. Kater, European Research Initiative on CLL (ERIC) Assessment of TP53 functionality
    » more
  • MDM2 SNP
    Coordinators: T. Zenz, A. Benner, Heidelberg/Germany
  • Comprehensive profiling of TP53 mutation in CLL
    Coordinators: S. Stilgenbauer, T. Zenz, S. Pospisilova, M. Trbusek, Brno/Czech Republic; D. Oscier, Bournemouth/UK, A. Pettitt, Liverpool/UK)
    Publications: TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
    T. Zenz, D. Vollmer, M. Trbusek, J. Smardova, A. Benner, T. Soussi, H. Helfrich, M. Heuberger, P. Hoth, M. Fuge, T. Denzel, S. Häbe, J. Malcikova, P. Kuglik, S. Truong, N. Patten, L. Wu, D. Oscier, R. Ibbotson, A. Gardiner, I Tracy, K Lin, A Pettitt, S Pospisilova, J Mayer, M Hallek, H Döhner, S Stilgenbauer, European Research Initiative on CLL (ERIC).
    Leukemia. 2010 Dec;24(12):2072-9

Flow Cytometry

  • ZAP70 harmonisation project
    Coordinators: R. Letestu, F. Cymbalista, Bobigny/ France
    » more
  • Harmonization and consensus in reporting the results of cytometric analysis of ZAP70
    Coordinators: F. Cymbalista, R. Letestu, Bobigny/France*
    Publications: Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process
    R. Letestu , A. Rawstron, P. Ghia, N. Villamor, N. Boeckx, S. Boettcher, AM. Buhl, J. Duerig, R. Ibbotson, A. Kroeber, A. Langerak, M. Le Garff-Tavernier, I Mockridge, A. Morilla, R. Padmore, L. Rassenti, M. Ritgen, M. Shehata, P. Smolewski, P. Staib, M. Ticchioni, C. Walker, F. Ajchenbaum-Cymbalista
    Cytometry B Clin Cytom. 2006 Jul 15;70(4):309-14
    » more

Recommendations and Standardization

  • ERIC consensus recommendations for IGHV gene mutational analysis
    Coordinators: P. Ghia (Milan, Italy); R. Rosenquist, Uppsala / Sweden)
    Publications: ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia
    Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, Davi F, Rosenquist R; European Research Initiative on CLL
    Leukemia, 2007 Jan;21(1):1-3
  • Standardization of a four-color diagnostic test for minimal residual disease (MRD) monitoring
    Coordinators: M. Ritgen and S. Boetcher (Kiel, Germany); A. Rawstron (Leeds, UK)
    Publications: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
    Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P
    Leukemia, 2007 May;21(5):956-64

Immunoglobin Gene Sequences

  • IG gene analysis in CLL: Prognostic and biological implications of cases difficult to categorize
    Coordinators: C. Belessi (Athens, Greece) and A. Langerak (Rotterdam, The Netherlands)
    Publications: Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases.
    Langerak AW, Davi F, Ghia P, Hadzidimitriou A, Murray F, Potter KN, Rosenquist R, Stamatopoulos K, Belessi C.
    Leukemia. 2011 Apr 1. [Epub ahead of print]
  • 6th Educational Workshop on Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia
    Coordinators: R. Rosenquist, Sweden, K. Stamatopoulos, Greece
    This Workshop, organized by the IgCLL group, working group within ERIC, was held in Uppsala from 22 -23 September 2016. It comprised of a mixture of lectures and applied sessions held by experts in the field on immunoglobulin gene analysis and interpretation in CLL. Participants were introduced to the scientific rationale for performing the diagnostic procedures and the basic principles of the relevant methodologies, being exposed to the actual practical work from the sample collection to the drafting of the final clinical report. This activity can also be extended to clinical study groups and industry partners to improve both the standardization of the assay and the interpretation of the results within investigator- or company-driven clinical trials. Should you wish to view the published presentations, then please click on the Past Meetings Section on the ERIC website.


  • Individualized modeling in CLL: the perspective of the clinicians
    P. Baliakas, Uppsala/Sweden
    » more
  • EBMT/ERIC recommendations for stem cell transplantation in T cell prolymphocytic leukemia (T-PLL) including criteria for the diagnosis of T-PLL
    Coordinator: P. Dreger (Heidelberg, Germany)
    PDF EBMT/ERIC recommendations for SCT in T-PLL
  • Phase IV Observational Study of Chronic Lymphocytic Leukemia (CLL) Patients Receiving Arzerra® (Ofatumumab)
    Coordinators: C. Moreno (Barcelona, Spain) and Colm Bradley (Houston, UK) Ofatumumab Trial eCRF
    Ofatumumab Trial eCRF (restricted website for ERIC members involved in the Ofatumumab trial)
  • Treatment of T-Prolymphocytic Leukemia with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab - phase II trial
    Coordinator: G. Hopfinger (Vienna, Austria) Leukemia & Lymphoma

Este sitio web ha sido creado y es gestionado mediante la tecnología uniweb, desarrollada por intelligenia.

Web - Ingeniería y Diseño - intelligenia